Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A.
Sands BE, et al. Among authors: siegel ca.
Inflamm Bowel Dis. 2024 Oct 25:izae253. doi: 10.1093/ibd/izae253. Online ahead of print.
Inflamm Bowel Dis. 2024.
PMID: 39448057